Arvinas (NASDAQ:ARVN) Releases Earnings Results

Arvinas (NASDAQ:ARVN) posted its quarterly earnings results on Tuesday. The company reported ($0.63) EPS for the quarter, topping the consensus estimate of ($1.07) by $0.44, Zacks reports. During the same period in the previous year, the business posted ($2.53) EPS.

Arvinas Stock Up 1.4 %

ARVN opened at $18.97 on Tuesday. Arvinas has a 52 week low of $16.61 and a 52 week high of $53.08. The business’s 50 day moving average is $19.46 and its two-hundred day moving average is $23.44.

Analysts Set New Price Targets

Several research firms have weighed in on ARVN. Cantor Fitzgerald reiterated an “overweight” rating on shares of Arvinas in a report on Friday. Guggenheim reiterated a “buy” rating on shares of Arvinas in a research report on Thursday, December 12th. Oppenheimer cut their target price on Arvinas from $50.00 to $40.00 and set an “outperform” rating for the company in a research note on Thursday, October 31st. HC Wainwright restated a “buy” rating and set a $87.00 price target on shares of Arvinas in a research note on Wednesday, December 11th. Finally, Stephens started coverage on shares of Arvinas in a research note on Monday, November 18th. They issued an “overweight” rating and a $55.00 price target for the company. One research analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $61.45.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.